The Filing Desk

Biodesix

BDSX · Nasdaq · Health Care · Financials, fiscal 2019 to 2025

BDSX · Last close · November 19, 2026
$8.30
Value Biodesix yourself

Biodesix's revenue rose 24.1% to $88 million in fiscal 2025. Its operating margin was −31.5%, up from −48.4% a year earlier. Free cash flow was −$24 million. The diluted share count rose 16.7%.

BIODESIX, INC. Latest fiscal year ended December 31, 2025 10-K filed February 26, 2026 · 0001193125-26-076547 Updated
Revenue
$88M
24.1%
Operating margin
−31.5%
16.9 pts
Net income
−$35M
 
Free cash flow
−$24M
 
Return on capital
−69.7%
33.1 pts
Market cap
$89M
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

About these figures. Share counts and per-share figures for earlier years are restated for a stock split (1-for-20), so every year is on today's share basis.

Charts show fiscal years, from the 10-K filings.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Biodesix lost money in fiscal 2025: a net loss of $35 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments3343262619
Debt incl. finance leases1030404050
Net debt (negative means net cash)−23−13141431
Net debt to EBITDA—————
Debt to equity0.5x1.5x—1.9x—
Interest coverage−9.1x−6.3x−4.3x−4.2x−3.6x
Current ratio1.5x2.3x1.2x2.8x1.9x
Quick ratio1.5x2.3x1.2x2.8x1.9x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Biodesix's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $3.1 million of Biodesix shares on the open market, and 5 insiders sold $104,401.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Aug 12, 2026Jack W Schuler10% ownerBought15,000$24.47$367,050Form 4
Aug 11, 2026Jack W Schuler10% ownerBought13,700$24.01$328,937Form 4
Aug 10, 2026Jack W Schuler10% ownerBought13,900$24.25$337,075Form 4
Feb 23, 2026Scott HuttonPresident & CEO, DirectorSold1,490$12.78$19,042Form 4
Feb 23, 2026Gary Anthony PestanoChief Development OfficerSold556$12.78$7,106Form 4
Feb 23, 2026Kieran O'KaneChief Commercial OfficerSold535$12.78$6,837Form 4
Feb 23, 2026Chris VazquezChief Accounting OfficerSold211$12.78$2,697Form 4
Feb 10, 2026Scott HuttonPresident & CEO, DirectorSold3,559$10.08$35,875Form 4
Feb 10, 2026Robin Harper CowieCFO, Sec'y & TreasurerSold941$10.08$9,485Form 4
Feb 10, 2026Kieran O'KaneChief Commercial OfficerSold584$10.08$5,887Form 4
Feb 10, 2026Gary Anthony PestanoChief Development OfficerSold540$10.08$5,443Form 4
Feb 10, 2026Chris VazquezChief Accounting OfficerSold101$10.08$1,018Form 4
The latest 12 of 18 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score3 of 84 of 83 of 8
Rule of 40−64.8%−27.4%−2.5%
Altman Z''−16.14−15.90−19.59
Accruals ratio−30.5%5.8%−13.0%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets rosePassPassPass
Cash from operations exceeds net incomePassFailPass
Debt fell relative to assetsFailPassFail
Current ratio roseFailPassFail
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assetsPassPassPass
F-score3 of 84 of 83 of 8
Companies that report no gross profit are scored on the other eight.

Compare

Put Biodesix side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
BiodesixFY2524.1%−31.5%−26.6%−69.7%—3
MDxHealthFY2519.8%−13.4%−3.1%−41.8%—3Compare
ExagenFY2519.6%−21.1%−21.4%−115.0%—3Compare
RidgetechFY2610.2%−1.4%−1.1%———Compare
GrailFY2517.2%−382.0%−203.8%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

7 years of figures

Fiscal yearFY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue25465438497188
Revenue growth—85.5%19.6%−29.9%28.5%45.3%24.1%
Gross profit———————
Research and development10111313101012
Operating income−27−23−41−51−41−34−28
Net income−31−65−43−65−52−43−35
Diluted EPS (US$)−2,539.40−129.60−31.60−31.00−12.80−6.64−4.67
Diluted shares (millions)0012468
Cash flow
Cash from operations−22−21−28−45−23−49−23
Capital expenditure12232330
Free cash flow−23−23−30−48−46−52−24
Dividends paid0000000
Share buybacks0000000
Acquisitions0000000
Stock-based compensation0456574
Balance sheet at fiscal year end
Cash and short-term investments5623343262619
Debt incl. finance leases36281030404050
Total assets451217693999788
Total liabilities76805672947690
Shareholders' equity−225412021521−2
Margins and ratios
Gross margin———————
Operating margin−108.9%−50.3%−75.1%−132.4%−84.2%−48.4%−31.5%
Net margin−125.2%−143.7%−79.2%−171.3%−106.2%−60.2%−39.9%
Free cash flow margin−93.8%−51.2%−55.9%−126.3%−93.3%−72.7%−26.6%
Rule of 40 (growth + FCF margin)—34.4%−36.2%−156.2%−64.8%−27.4%−2.5%
Return on capital————−251.1%−102.8%−69.7%
Return on equity——−141.8%−324.5%−414.1%−337.3%−383.1%
Return on assets—−78.8%−43.8%−77.5%−54.3%−43.7%−38.2%
Net debt to EBITDA———————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Biodesix's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Biodesix.